Pilot / Feasibility Grant Application Instructions
Background
The Rare Lung Diseases Consortium (RLDC) administrative core supports three pilot and feasibility awards per year at $25,000 each. Grants will be awarded for one year, with a second year contingent on a progress report including a formal presentation.
Purpose
The awards are intended to support pilot or feasibility projects related to one of the four targeted diseases of the Rare Lung Diseases Consortium: alpha-1 antitrypsin deficiency (AATD), lymphangioleimyomatosis (LAM), pulmonary alveolar proteinosis (PAP) and hereditary interstitial lung diseases (hILD).
They may fall into the realm of basic science, translational, or clinical studies. Priority will be given to hypothesis-driven projects involving human subjects that are likely to lead to extramural funding, make novel scientific contributions, or facilitate new clinical trials.
Deadlines
Application: Jan. 31, 2005
Budget
Funds may be used for technical support and supplies. Funds are not to be used for travel or salary support.
Eligibility
Applications will only be accepted from RLDC investigators or clinical fellows.
Process
Applications will be reviewed by a committee comprised of RLDC investigators, scientific directors of the relevant patient foundations and external ad hoc reviewers with expertise in the proposed area of investigation.
Letter of Support
Full applications must include a letter of support from the primary applicant's chairperson. Included in the letter of support must be a statement regarding the priority of the research proposal for the division, particularly as it relates to patient resources.
Required Format
Proposals must be submitted in single-spaced text, one-half inch margins in 12-point font. The primary applicant's name must appear in the upper right hand corner of each page. Proposal text must be limited to five pages (including figures but excluding references). Proposals must use standard PHS 398 forms. Budget, biosketch, other support and resources may also be used.
Submission Guidelines
All applications must be submitted by email to Carol Johnson (carol.johnson@cchmc.org) and received by 5 pm on Jan. 31, 2005. Applications that do not adhere to these guidelines will not be considered.
Contact Us
For questions regarding these instructions, please contact Carol Johnson, administrator (carol.johnson@cchmc.org) or Tim Cripe, Translational Research Trials Office director (timothy.cripe@cchmc.org).
